4597
Solasia Pharma K.K.
ソレイジア・ファーマ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- IFRS
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Dec 2021
559
Dec 2022
1,092
Dec 2023
617
Dec 2024
316
Dec 2025
429
Operating profit(million JPY)
Dec 2021
-2,419
Dec 2022
-2,470
Dec 2023
-1,139
Dec 2024
-1,951
Dec 2025
-861
Operating profit margin(%)
Dec 2021
-432.74
Dec 2022
-226.19
Dec 2023
-184.6
Dec 2024
-617.41
Dec 2025
-200.7
Profit before tax(million JPY)
Dec 2021
-2,442
Dec 2022
-2,492
Dec 2023
-1,135
Dec 2024
-1,961
Dec 2025
-876
Profit(million JPY)
Dec 2021
-2,478
Dec 2022
-2,548
Dec 2023
-1,112
Dec 2024
-1,941
Dec 2025
-876
Total assets(million JPY)
Dec 2021
3,144
Dec 2022
3,134
Dec 2023
2,229
Dec 2024
1,362
Dec 2025
2,145
Cash and cash equivalents(million JPY)
Dec 2021
714
Dec 2022
803
Dec 2023
728
Dec 2024
886
Dec 2025
1,387
Cash flows from operating activities(million JPY)
Dec 2021
-2,473
Dec 2022
-2,074
Dec 2023
-359
Dec 2024
-1,033
Dec 2025
-847
Cash flows from investing activities(million JPY)
Dec 2021
-164
Dec 2022
-418
Dec 2023
0
Dec 2024
0
Dec 2025
-81
Cash flows from financing activities(million JPY)
Dec 2021
361
Dec 2022
2,571
Dec 2023
275
Dec 2024
1,180
Dec 2025
1,425
Return on equity(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Equity ratio(%)
Dec 2021
82.3
Dec 2022
84.9
Dec 2023
84.1
Dec 2024
84.9
Dec 2025
81.7
Earnings per share(JPY per share)
Dec 2021
-19.04
Dec 2022
-16.77
Dec 2023
-6.62
Dec 2024
-9.77
Dec 2025
-3.69
Net assets per share(JPY per share)
Dec 2021
19.38
Dec 2022
15.85
Dec 2023
10.78
Dec 2024
5.3
Dec 2025
6.65
Dividend per share(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Payout ratio(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.